Results 281 to 290 of about 27,849,568 (325)

Functional impact of IBS-D microbiota on the gut-brain axis

Brain, Behavior, and Immunity, 2015
Irritable Bowel Syndrome (IBS) is a common disorder characterized by altered gut function and frequent psychiatric co-morbidity. Although altered intestinal microbiome profiles have been documented, their relevance to the clinical expression of IBS is unknown.
G. De Palma, M.D. Lynch, L. Jun, V.T. Dang, Y. Deng, J. Jury, G. Umeh, P.M. Miranda, M. Pigrau, S. Sidani, P.G. McLean, G. Moreno-Hagelsieb, M.G. Surette, G.E. Bergonzelli, E.F. Verdu, P. Britz-McKibbin, J.D. Neufeld, S.M. Collins, P. Bercik   +18 more
openaire   +1 more source

Is Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) a Myth?

Medical Research Archives, 2022
The prevalence of Diarrhea Predominant Irritable Bowel Syndrome (IBS D) and chronic diarrhea has been one of the most troublesome diagnoses inflicting approximately 5% of the population annually. These entities have always perplexed physicians that attempt to offer relief to millions of sufferers. Because of the magnitude of the problem, physicians and
openaire   +1 more source

Revival of 5-HT3 antagonism as treatment of IBS-D?

Gut, 2014
While drug development for chronic constipation and IBS with constipation has moved ahead with the marketing of prucalopride and linaclotide in many countries, the development of agents for functional diarrhoea and IBS-D has been more troubled. With the limited availability of the serotonin (5-HT)3 antagonist alosetron, the global market of drugs for ...
openaire   +2 more sources

Getting the BS out of Irritable Bowel Syndrome with Diarrhea (IBS-D): Let’s Make a Diagnosis

Current Gastroenterology Reports, 2023
C. Frissora, Lawrence R. Schiller
semanticscholar   +1 more source

Diarrhea Predominant Irritable Bowel Syndrome (IBS-D): Fact or fiction

Medical Hypotheses, 2011
Diarrhea Predominant Irritable Bowel Syndrome IBS (IBS-D) and functional diarrhea constitute 50% of cases treated by gastroenterology specialists and a significant proportion of those treated in a primary physicians practice. The size of the problem and the difficulty in successfully addressing these entities has frustrated patients and physicians ...
openaire   +2 more sources

IBS-D

2023
W. Harley Sobin, Patrick Sanvanson
openaire   +1 more source

Sa607 A PHASE II STUDY OF LIVE BIOTHERAPEUTIC BLAUTIX IN IRRITABLE BOWEL SYNDROME (IBS) PATIENTS WITH SUBTYPES IBS-D AND IBS-D

Gastroenterology, 2021
Alex Stevenson, Axel Glasmacher, Louise Markinson, Charlie Badham, Eamonn M. Quigley   +4 more
openaire   +1 more source

Ramosetron Is Effective in Women With IBS-D

MD Conference Express, 2015
L. Lederman, S. Fukudo
openaire   +1 more source

An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D.

Gastroenterology & hepatology, 2014
Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder and affects up to 12% to 15% of adults in the United States, with a higher prevalence among women and those younger than 50 years. IBS adversely impacts quality of life and medical expenditures, with significant costs arising from healthcare visits and reduced ...
Brian E, Lacy, William D, Chey, Lin, Chang   +2 more
openaire   +1 more source

Safety of Eluxadoline in Patients With IBS-D Without a Gallbladder

American Journal of Gastroenterology, 2017
Brooks D, Cash, Brian E, Lacy, Philip S, Schoenfeld, Leonard S, Dove, Paul S, Covington   +4 more
openaire   +2 more sources